STOCK TITAN

ResMed Announces Leadership Change

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

ResMed (NYSE: RMD) has announced the immediate departure of Jim Hollingshead, who served as the President of Sleep and Respiratory Care, after 12 years with the company. Rob Douglas has been appointed as interim President. CEO Mick Farrell acknowledged Hollingshead’s significant contributions to ResMed, particularly in digital health transformation. The transition aims to maintain strong leadership as the company positions itself for continued growth into 2025 and beyond.

Positive
  • Rob Douglas’s interim leadership may provide continuity during the transition.
  • The appointment of an interim president signals ResMed's commitment to maintaining leadership strength.
Negative
  • Jim Hollingshead's departure could create a gap in leadership experience within the Sleep and Respiratory Care division.

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care. 

“I’d like to thank Jim for his 12 years of service and valuable contributions to ResMed,” said Mick Farrell, ResMed CEO. “Jim has played an important role in our business, first as head of our strategy and business development team, then as president of our Americas region, and most recently as president of our Sleep and Respiratory Care business. Jim formed part of the global business team that created the strategy to embed communications in our devices, supporting our transformation into a world-leading digital health company. Together with our CEO operations team, Jim has helped curate a team of strong leaders, leaving ResMed well positioned for ongoing growth, as we accelerate our business into 2025, and beyond. I wish Jim well in his new role as a ResMed alum, and I thank Rob for stepping in on an interim basis, as together we build upon our strong leadership bench-strength here at ResMed.”

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For media
Jayme Rubenstein
+1 858-836-6798
news@resmed.com
For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

FAQ

What led to Jim Hollingshead's departure from ResMed?

Jim Hollingshead accepted a new position outside the company.

Who is the new interim President of Sleep and Respiratory Care at ResMed?

Rob Douglas has been appointed as the interim President.

How will Jim Hollingshead's departure impact ResMed?

His departure may temporarily disrupt leadership continuity in the Sleep and Respiratory Care division.

What contributions did Jim Hollingshead make during his tenure at ResMed?

He played a crucial role in strategy development and digital health transformation for the company.

What is ResMed's focus moving forward after the leadership change?

The company aims to accelerate growth and maintain strong leadership as it approaches 2025.

ResMed Inc.

NYSE:RMD

RMD Rankings

RMD Latest News

RMD Stock Data

35.79B
145.66M
0.77%
61.33%
5.38%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO